Percutaneous aortic valve replacement

Global Transcatheter Heart Valve Market Set to Reach $15.14 Billion by 2030 with a Strong CAGR of 12.73% - ResearchAndMarkets.com

Retrieved on: 
Friday, July 28, 2023
Research, Medical Devices, Technology, Hospitals, Health Technology, Science, Surgery, Cardiology, Biotechnology, Other Technology, Other Science, Health, Prevalence, Ageing, TAVI, Aortic stenosis, Percutaneous aortic valve replacement, Patient, Physician, Risk, Tissue engineering, Aortic valve, TAVR, Growth, Abdominal ultrasonography, Valvular heart disease, Medical device, Medical imaging

Aortic stenosis, a condition characterized by the incomplete opening of the aortic valve, has driven the need for transcatheter aortic valve implantation.

Key Points: 
  • Aortic stenosis, a condition characterized by the incomplete opening of the aortic valve, has driven the need for transcatheter aortic valve implantation.
  • The rising prevalence of aortic stenosis, along with improved surgical techniques and growing demand for surgical technologies, is propelling the transcatheter aortic valve replacement (TAVR) market.
  • Transcatheter Aortic Valve Replacement (TAVR) has emerged as the leading procedure in the global medical market, capturing the highest market share.
  • In conclusion, the global transcatheter heart valve market is set for significant growth, reaching an estimated value of US$ 15.14 Billion by 2030.

Valve Medical Announces Successful First-in-Human Implantation of Ultra-low Profile TAVR Valve in Israel

Retrieved on: 
Wednesday, May 31, 2023
Rabin Medical Center, Aortic stenosis, TEL, Percutaneous aortic valve replacement, Patient, Physician, Risk, Aortic valve, TAVR, Workload, FIH, Medical imaging, Dentistry

TEL AVIV, Israel, May 31, 2023 /PRNewswire/ -- Valve Medical, a wholly owned subsidiary of Medinol Ltd. is pleased to announce today the successful First-in-Human (FIH) implantation of their advanced Transcatheter Aortic Valve Replacement (TAVR) system in Israel, introducing a revolutionary advancement in Structural Heart procedures with the world's first modular valve.

Key Points: 
  • TEL AVIV, Israel, May 31, 2023 /PRNewswire/ -- Valve Medical, a wholly owned subsidiary of Medinol Ltd. is pleased to announce today the successful First-in-Human (FIH) implantation of their advanced Transcatheter Aortic Valve Replacement (TAVR) system in Israel, introducing a revolutionary advancement in Structural Heart procedures with the world's first modular valve.
  • The Valve Medical Xemed TAVR device is a transformational technology designed to improve patient outcomes and procedural success.
  • The distinguishing feature of the valve is its modular design, which has an ultra-low profile, enabling the use of a standard 12 Fr sheath.
  • TAVR is a minimally invasive procedure that replaces the damaged aortic valve with a new valve without the need for open-heart surgery.

Morton Plant First in Florida to Participate in Trial to Expand TAVR to Aortic Regurgitation Patients

Retrieved on: 
Wednesday, February 1, 2023
Fatigue, Align, Physician, Blood, Aortic regurgitation, Winter Haven Hospital, Saint Joseph, Patient, Hospital, Suture, Aortic stenosis, Dignity Health St. Joseph's Hospital and Medical Center, Morton, TAVR, Chest pain, BayCare Ballpark, Morton Plant Hospital, Groin, Heart, Percutaneous aortic valve replacement, Femoral artery, FACS, Aortic valve, Quality of life, Heart failure, Calcium, Trilogy, Tricuspid valve, Medical imaging, Tampa Bay, MD

The team has been using the minimally invasive TAVR procedure to treat patients with aortic stenosis since 2012, when Morton Plant became the first hospital in the Tampa Bay area to offer TAVR.

Key Points: 
  • The team has been using the minimally invasive TAVR procedure to treat patients with aortic stenosis since 2012, when Morton Plant became the first hospital in the Tampa Bay area to offer TAVR.
  • The Align trial is the first use of a TAVR valve designed to treat primary aortic regurgitation in a native valve by the Morton Plant team.
  • Aortic stenosis is the narrowing of the aortic valve, which restricts blood flow to the heart.
  • In patients with aortic regurgitation or aortic insufficiency, blood pumped from the left ventricle leaks back into the heart because the aortic valve doesn't close properly.

Memorial Healthcare System's Transition to an Academic Medical Center Benefitting Physicians and Patients

Retrieved on: 
Tuesday, August 30, 2022
Cardiovascular disease, Guideline, MHS, Program, Research, Aortic valve, GME, Percutaneous aortic valve replacement, Memorial Hermann Health System, Aortic stenosis, Heart failure, Collection, Interventional cardiology, Physician, Graduate medical education, Hospital, Heart, Stenosis, Population, Education, Nursing, Clinical trial, Jose B. Lingad Memorial Regional Hospital, TAVR, Patient, Medicine, Medical device, Medical imaging

HOLLYWOOD, Fla., Aug. 30, 2022 /PRNewswire-PRWeb/ -- Longtime healthcare industry observers may remember Memorial Healthcare System (MHS) as a collection of community hospitals that provided quality care to regional audiences. Its cardiac program exemplified the patient and family-centered approach the system and its specialists took when offering clinical services.

Key Points: 
  • HOLLYWOOD, Fla., Aug. 30, 2022 /PRNewswire-PRWeb/ -- Longtime healthcare industry observers may remember Memorial Healthcare System (MHS) as a collection of community hospitals that provided quality care to regional audiences.
  • And while that's still true at the core, it's now just the foundation upon which an academic medical center has been built.
  • When Memorial received initial institutional accreditation to start a Graduate Medical Education (GME) program in 2015, it took a quantum leap forward as a healthcare provider.
  • "Will patients with only moderate aortic stenosis receive a benefit with aortic valve replacement above medical therapy?

DGAP-News: Pi-Cardia Successfully Performs Mitral Valve Splitting With ShortCut™

Retrieved on: 
Monday, August 22, 2022
Mortality, Disease, Heart, Percutaneous aortic valve replacement, Hemodynamics, Aortic stenosis, Mitral valve, San Raffaele Hospital, Intention, TMVR, Obstruction, Risk, Adrenal insufficiency, TAVR, Patient, LVOT, Medical imaging, Medical device

Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based solutions for treating heart valves, announced today a successful First-In-Human treatment of the mitral valve with the ShortCut Mitral device in Europe.

Key Points: 
  • Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based solutions for treating heart valves, announced today a successful First-In-Human treatment of the mitral valve with the ShortCut Mitral device in Europe.
  • ShortCut is the worlds first dedicated device designed to split the leaflets prior to transcatheter valve treatment in patients at risk for coronary obstruction after Transcatheter Aortic Valve Replacement (TAVR) or left ventricular outflow tract (LVOT) obstruction after Transcatheter Mitral Valve Replacement (TMVR).
  • The ShortCut Mitral compassionate case was performed at the University Hamburg Eppendorf, Germany, by Prof. Lenard Conradi and Dr. Niklas Schofer, in collaboration with Dr. Paolo Denti.
  • With the ShortCut Mitral device, we will now be able to treat more patients with mitral valve disease who otherwise have no other option.

Transcatheter Aortic Valve Replacement Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures, and Forecast, 2015-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 17, 2022
Medical Devices, Health, Country, ASP, Aortic stenosis, Percutaneous aortic valve replacement, Patient, COVID-19, SWOT, Aortic valve, SWOT analysis, Region, Steel, Retail, Medical imaging, Medical device, Forecast

Transcatheter Aortic Valve Replacement Market Report is built to visualize quantitative market trends within Cardiovascular Devices therapeutic area.

Key Points: 
  • Transcatheter Aortic Valve Replacement Market Report is built to visualize quantitative market trends within Cardiovascular Devices therapeutic area.
  • The model discusses in detail the impact of COVID-19 on Transcatheter Aortic Valve Implantation market for the year 2020 and beyond.
  • Transcatheter aortic valve implantation is used in patients who are elderly or are at a high risk for surgery and have severe symptomatic aortic valve stenosis.
  • While aortic valve replacement remains the gold standard therapy, transcatheter aortic valve Replacement, also known as transcatheter aortic valve implantation has been identified as an alternative in elderly patients, inoperable or of higher surgical risk, and its suitability as a replacement for surgical aortic valve implantation is being explored due to lower operation and recovery times.

Hoag Recognized as Highest Ranked Hospital in Orange County for Top-Quality Care by U.S. News & World Report's 2022-2023 Best Hospitals Rankings

Retrieved on: 
Tuesday, July 26, 2022
Heart failure, Spinal fusion, TAVR, Physician, CEO, U.S. News & World Report Best Hospitals Rankings, ANCC, Percutaneous aortic valve replacement, Health, Stroke, Journal of Neurology, Neurosurgery, and Psychiatry, Adult, Chronic obstructive pulmonary disease, Multimedia, News, Cancer, U.S. News & World Report, Neuroscience, Leadership, Hospital, Asa, Nursing, American Nurses Credentialing Center, Patient, Neurology, Heart, Digestive system surgery, Myocardial infarction, COPD, Diabetes, Gastroenterology, Urology, OC, Elective surgery, Medicine, Pneumonia, Geriatrics

NEWPORT BEACH, Calif., July 26, 2022 /PRNewswire/ -- For the sixth consecutive year, U.S. News & World Report's 2022-2023 Best Hospitals Rankings named Hoag Memorial Hospital Presbyterian the highest ranked hospital in Orange County, the fourth-best hospital in the Los Angeles metro area and ninth-best in California. The rankings also included national rankings in three specialty areas and recognition for Hoag's high performance in 19 specialty procedures and conditions.

Key Points: 
  • NEWPORT BEACH, Calif., July 26, 2022 /PRNewswire/ -- For the sixth consecutive year, U.S. News & World Report's 2022-2023 Best Hospitals Rankings named Hoag Memorial Hospital Presbyterian the highest ranked hospital in Orange County, the fourth-best hospital in the Los Angeles metro area and ninth-best in California.
  • The rankings also included national rankings in three specialty areas and recognition for Hoag's high performance in 19 specialty procedures and conditions.
  • The annual Best Hospitals rankings and ratings serve as an important resource to assist patients and their doctors in making informed decisions about where to receive care for challenging health conditions and common elective procedures.
  • To view the full rankings of U.S. News & World Report, visit Best Hospitals .

DGAP-News: Pi-Cardia Receives FDA IDE Approval for Pivotal Study with ShortCut(TM) Device

Retrieved on: 
Tuesday, July 26, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Investigational device exemption, Time, TAVR, Food, ISRAEL, Aortic stenosis, Heart, Intention, Percutaneous aortic valve replacement, Risk, University Medical Center, Premolar, Safety, Structural heart disease, FDA, MD, Patient, Hemodynamics, IDE, Growth, Medical device

REHOVOT, ISRAEL / ACCESSWIRE / July 26, 2022 / Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based solutions for treating heart valves, announced today it received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to commence the ShortCut Pivotal Study, which will assess the safety and effectiveness of the ShortCut device.

Key Points: 
  • REHOVOT, ISRAEL / ACCESSWIRE / July 26, 2022 / Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based solutions for treating heart valves, announced today it received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to commence the ShortCut Pivotal Study, which will assess the safety and effectiveness of the ShortCut device.
  • The TAVR market, currently estimated at $6 billion, is projected to double over the next five years, with the expansion into low-risk younger patients.
  • Pi-Cardia's Leaflex device mechanically scores valve calcification at multiple locations, with the intention of restoring leaflet flexibility and improving valve hemodynamics.
  • The ShortCut device and Leaflex device are investigational devices, limited by United States law for investigational use.

PIH Health Good Samaritan Hospital First in LA to Use Next-Generation Evolut™ FX TAVR System

Retrieved on: 
Wednesday, July 13, 2022
PIH, Round Top hospitals, Elective surgery, College, Health, Percutaneous aortic valve replacement, Multimedia, SSAS, TAVR, PIH Health, Patient, Instagram, Food, Heart, IBM Watson Health, Physician, Heart failure, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hospice, Hospital, College of Healthcare Information Management Executives, Quality of life, Twitter, Aortic stenosis, CHIME, Cancer, Facebook, Food Evolution

LOS ANGELES, July 13, 2022 /PRNewswire/ -- PIH Health Good Samaritan Hospital is the first hospital in Los Angeles to treat patients with the next-generation, self-expanding Evolut FX Transcatheter Aortic Valve Replacement (TAVR) System, a minimally invasive alternative to open-heart surgical aortic valve replacement for the treatment of symptomatic severe aortic stenosis (ssAS). The first patient was treated on June 29, 2022.

Key Points: 
  • LOS ANGELES, July 13, 2022 /PRNewswire/ -- PIH Health Good Samaritan Hospital is the first hospital in Los Angeles to treat patients with the next-generation, self-expanding Evolut FX Transcatheter Aortic Valve Replacement (TAVR) System, a minimally invasive alternative to open-heart surgical aortic valve replacement for the treatment of symptomatic severe aortic stenosis (ssAS).
  • The U.S. Food and Drug Administration recently approved the Evolut FX TAVR system, providing physicians at PIH Health Good Samaritan Hospital another option to treat the growing symptomatic severe aortic stenosis (ssAS) patient population.
  • Patients with ssAS should discuss TAVR with their PIH Health doctor to evaluate if the procedure is right for them.
  • The fully integrated network is comprised of PIH Health Downey Hospital, PIH Health Good Samaritan Hospital, PIH Health Whittier Hospital, 35 outpatient medical office buildings, a multispecialty medical (physician) group, home healthcare services and hospice care, as well as heart, cancer, digestive health, orthopedics, women's health, urgent care and emergency services.

BayCare Receives Recognition for its Minimally Invasive Transcatheter Valve Procedures

Retrieved on: 
Thursday, June 23, 2022
IBM, Patient, Multimedia, Certification, ACC, St. Joseph's Hospital (St. Paul, Minnesota), Hospital, TAVR, Heart failure, BayCare Ballpark, Winter Haven Hospital, Percutaneous aortic valve replacement, Risk, Heart, Program, Medicare, Blood, FACS, Surgeon, Practitioner, Evidence-based medicine, American College, Aortic stenosis, Health, Cardiology, Structural heart disease, Disease, Tampa Bay, St. Joseph's Hospital, Laboratory, Knowledge, Quality of life, Morton Plant Hospital, Center, Aortic valve, Time, Pharmaceutical industry, Medicine, Online shopping, MD

The certification recognizes each program's expertise and commitment to excellence in treating patients receiving transcatheter valve repair and replacement procedures.

Key Points: 
  • The certification recognizes each program's expertise and commitment to excellence in treating patients receiving transcatheter valve repair and replacement procedures.
  • This causes the heart to work harder to push blood through the calcified aortic valve.
  • Before Transcatheter Aortic Valve Replacement (TAVR), the primary solution for patients suffering from aortic stenosis was open heart surgery, which was not an option for many people.
  • Participation in established national clinical databases is required for hospitals interested in achieving Transcatheter Valve Certification.